TY - JOUR
T1 - Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
T2 - Results From CORALE-IBD
AU - the CORALE-IBD Study Group
AU - Li, Dalin
AU - Debbas, Philip
AU - Mujukian, Angela
AU - Cheng, Susan
AU - Braun, Jonathan
AU - McGovern, Dermot P.B.
AU - Melmed, Gil Y.
AU - Banty, Andrea
AU - Feldman, Edward
AU - Ha, Christina
AU - Lee, Susie
AU - Rabizadeh, Shervin
AU - Stein, Theodore
AU - Solomon, Theodore
AU - Syal, Gaurav
AU - Targan, Stephan
AU - Vasiliauskas, Eric
AU - Ziring, David
AU - Bonthala, Niru
AU - Botwin, Gregory S.
AU - Hampton, Melissa
AU - Mengesha, Emebet
AU - Khanishian, Elizabeth
AU - Pozdnyakova, Valeriya
AU - Gu, Phillip
AU - White, Shane
AU - Zamudio, Cindy
AU - Gonzalez, Daniel
AU - Parry, Alyssa
AU - Hanna, Mary
AU - Chan, Justin
AU - Ebinger, Joe
AU - Joung, Sandy
AU - Wu, Min
AU - Hoang, Amy
AU - Wynter, Timothy
AU - Sun, Nancy
AU - Figueiredo, Jane C.
AU - Merchant, Akil
AU - Merin, Noah
AU - Reckamp, Karen L.
AU - Appel, Keren
AU - Kumar, Rashmi
AU - Boland, Brigid
AU - Charabaty, Aline
AU - Chiorean, Michael
AU - Cohen, Erica
AU - Flynn, Ann
AU - Valentine, John
AU - Fudman, David
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Background: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown. Methods: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD. Results: The study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse. Conclusion: The frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.
AB - Background: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown. Methods: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD. Results: The study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse. Conclusion: The frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.
UR - http://www.scopus.com/inward/record.url?scp=85152767808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152767808&partnerID=8YFLogxK
U2 - 10.1093/ibd/izac174
DO - 10.1093/ibd/izac174
M3 - Article
C2 - 35998072
AN - SCOPUS:85152767808
SN - 1078-0998
VL - 29
SP - 883
EP - 887
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 6
ER -